Friday saw a verdict in the long running courtcase (6 years) between Phadia and Bioporto.
Phadia (now owned by Thermo Fischer) had a patent on NGAL - supposedly covering all human diseases. The patent has never been used actively by Phadia, but the rights to pursue the Patent has been given to Abbott - who wanted to use it as a legal base for their Architect heterogenous NGAL Test.
Friday - Abbott lost the case, in spite of showing up with the most prestigious Lawyers in Scandinavia - a case that ultimately will give BioPorto unhindered and exclusive market access (and close the door for effectively Abbott) to a market that is potentially as large as the heartmarker Toponin's - billions of dollars yearly...
read about the verdict - and its implications:
http://medicoinvestor.com/ngal-bioporto-and-phadia-i-medwatch-dk/
http://medicoinvestor.com/ngal-bioporto-and-phadia-i-medwatch-dk/
Phadia (now owned by Thermo Fischer) had a patent on NGAL - supposedly covering all human diseases. The patent has never been used actively by Phadia, but the rights to pursue the Patent has been given to Abbott - who wanted to use it as a legal base for their Architect heterogenous NGAL Test.
Friday - Abbott lost the case, in spite of showing up with the most prestigious Lawyers in Scandinavia - a case that ultimately will give BioPorto unhindered and exclusive market access (and close the door for effectively Abbott) to a market that is potentially as large as the heartmarker Toponin's - billions of dollars yearly...
read about the verdict - and its implications:
http://medicoinvestor.com/ngal-bioporto-and-phadia-i-medwatch-dk/
http://medicoinvestor.com/ngal-bioporto-and-phadia-i-medwatch-dk/